About this Research Topic
Since the beginning of the 21st century, epigenetics has entered a period of rapid development, especially in the field of biology and medicine. More and more clinical drugs have been found and approved. However, these clinical drugs can only target limited patient profiles. There is a huge heterogeneity in various tumors, for which higher requirements for the basic research of clinical problems are needed. From the public to academia, epigenetics research has been accumulating attention, which makes it necessary to further examine the progress and significance of epigenetics development. Despite that epigenetic drugs have unique advantages in the clinical treatment of hematological malignancies, such as Leukemia, research on genetics and epigenetics in the mechanisms and pathogenesis of hematological malignancies still needs to be further strengthened and deepened.
This research topic aims to elucidate the recent progress and advances on the mechanism of occurrence, drug resistance and relapse of acute leukemia from the perspective of genetics and/or epigenetics as well as their synergy and network regulation, especially for some subtypes of acute leukemia, such as AML1-ETO, PML-RARA and Bcr-Abl. We also welcome discussions on the genetic and epigenetic changes in immunotherapy.
We welcome submissions of Original Research, Review, Case Reports, Editorials, Perspective, Commentaries, Technical Notes and more, on the subtopics below:
1) How genetics and epigenetics interact and coordinate with each other in the development of leukemia, and what’s the downstream targets?
2) How genetics and epigenetics regulate chemotherapy resistance of leukemia and what’s the signaling pathway?
3) Besides DNA epigenetic modification, how does mRNA epigenetic modification participate in the occurrence and development of leukemia?
4) What are the roles for genetics and epigenetics in the process of leukemia immunotherapy and what’s the specific targets?
5) What is the mechanism of epigenetic drugs in the treatment of leukemia?
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
This research topic aims to elucidate the recent progress and advances on the mechanism of occurrence, drug resistance and relapse of acute leukemia from the perspective of genetics and/or epigenetics as well as their synergy and network regulation, especially for some subtypes of acute leukemia, such as AML1-ETO, PML-RARA and Bcr-Abl. We also welcome discussions on the genetic and epigenetic changes in immunotherapy.
We welcome submissions of Original Research, Review, Case Reports, Editorials, Perspective, Commentaries, Technical Notes and more, on the subtopics below:
1) How genetics and epigenetics interact and coordinate with each other in the development of leukemia, and what’s the downstream targets?
2) How genetics and epigenetics regulate chemotherapy resistance of leukemia and what’s the signaling pathway?
3) Besides DNA epigenetic modification, how does mRNA epigenetic modification participate in the occurrence and development of leukemia?
4) What are the roles for genetics and epigenetics in the process of leukemia immunotherapy and what’s the specific targets?
5) What is the mechanism of epigenetic drugs in the treatment of leukemia?
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: Leukemia, Epigenetics, Genetics, Immunotherapy, N6-methyladenosine
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
